脉管复康片联合氯吡格雷治疗冠状动脉粥样硬化性心脏病的效果研究

Study on the effect of Maiguan Fukang tablet combined with clopidogrel on the treatment of coronary atherosclerotic heart disease

目的研究脉管复康片联合氯吡格雷治疗冠状动脉粥样硬化性心脏病的临床效果。方法100例冠状动脉粥样硬化性心脏病患者,按照随机数字表法分为氯吡格雷组和两药联合组,各50例。氯吡格雷组患者使用氯吡格雷进行治疗,两药联合组采用脉管复康片联合氯吡格雷治疗。比较两组患者治疗前后心功能指标[左室射血分数(LVEF)、左室收缩末期内径(LVESD)、左室舒张末期内径(LVEDD)]、血清学指标[内皮素-1(ET-1)、一氧化氮(NO)水平、脑钠肽(BNP)、血管内皮生长因子(VEGF)]水平及心血管不良事件发生情况、治疗效果、不良反应发生情况。结果治疗后,两组患者LVEF大于治疗前,LVESD、LVEDD小于治疗前,且两药联合组患者LVEF大于氯吡格雷组,LVESD、LVEDD小于氯吡格雷组,差异有统计学意义(P<0.05)。治疗后,两组患者ET-1、BNP水平均低于治疗前,NO、VEGF水平高于治疗前,且两药联合组患者ET-1、BNP水平低于氯吡格雷组,NO、VEGF水平高于氯吡格雷组,差异有统计学意义(P<0.05)。两药联合组患者心力衰竭、心源性猝死、心绞痛发生率分别为12.00%、10.00%、4.00%,均低于氯吡格雷组的30.00%、26.00%、16.00%,差异有统计学意义(P<0.05)。两药联合组患者治疗总有效率90.00%高于氯吡格雷组的72.00%,差异有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论脉管复康片联合氯吡格雷治疗冠状动脉粥样硬化性心脏病效果显著,可有效改善患者心功能,降低心血管不良事件发生率。

Objective To study the clinical effect of Maiguan Fukang tablet combined with clopidogrel on the treatment of coronary atherosclerotic heart disease.Methods A total of 100 patients with coronary atherosclerotic heart disease were divided into clopidogrel group and combination group according to the random numerical table,each with 50 cases.Patients in the clopidogrel group were treated with clopidogrel,and patients in the combination group were treated with Maiguan Fukang tablets in combination with clopidogrel.Both groups were compared in terms of cardiac function indexes[left ventricular ejection fraction(LVEF),left ventricular end systolic diameter(LVESD),left ventricular end diastolic diameter(LVEDD)],serum indexes[endothelin-1(ET-1),nitric oxide(NO),brain natriuretic peptide(BNP),vascular endothelial growth factor(VEGF)]before and after treatment,cardiovascular adverse events,therapeutic effects,and occurrence of adverse reactions.Results After treatment,the LVEF of the two groups was greater than that of this group before treatment,and the LVESD and LVEDD were less than those of this group before treatment;the LVEF of the combination group was greater than that of the clopidogrel group,and the LVESD and LVEDD were less than those of the clopidogrel group.All differences were statistically significant(P<0.05).After treatment,the ET-1 and BNP of the two groups were lower than those of this group before treatment,and the NO and VEGF were higher than those of this group before treatment;the ET-1 and BNP of the combination group were lower than those of the clopidogrel group,and the NO and VEGF were higher than those of the clopidogrel group.All difference were statistically significant(P<0.05).The incidence of heart failure,sudden cardiac death,and angina pectoris in the combination group were 12.00%,10.00%,and 4.00%,which were lower than 30.00%,26.00%,and 16.00%in the clopidogrel group,and the difference was statistically significant(P<0.05).The total effective rate of treatment 90.00%in the combination group was higher than 72.00%in the clopidogrel group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two drugs(P>0.05).Conclusion Maichuan Fukang tablet in combination with clopidogrel is effective in the treatment of patients with coronary atherosclerotic heart disease,and can effectively improve the cardiac function of patients and reduce the incidence of cardiovascular adverse events.